Laboratoires Servier Sustainability Profile
Laboratoires Servier, a prominent French pharmaceutical company, is headquartered in Suresnes, France. Founded in 1954, Servier has established itself as a key player in the global healthcare industry, with a strong presence in Europe, Asia, and Africa. The company focuses on innovative treatments in various therapeutic areas, including cardiology, diabetes, oncology, and neurology. Servier is renowned for its commitment to research and development, investing significantly in new drug discovery and development. Its core products, such as the antihypertensive medication Perindopril, exemplify the company's dedication to improving patient outcomes through unique formulations and comprehensive treatment solutions. With a robust portfolio and a reputation for quality, Laboratoires Servier continues to strengthen its market position, achieving notable milestones in both innovation and patient care.
DitchCarbon Score
How does Laboratoires Servier's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Laboratoires Servier's score of 49 is higher than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Laboratoires Servier's reported carbon emissions
In 2024, Laboratoires Servier reported total carbon emissions of approximately 69,904,000 kg CO2e for Scope 1 and about 33,048,000 kg CO2e for Scope 2. This marks a slight decrease from 2023, where emissions were approximately 71,457,000 kg CO2e for Scope 1 and 36,432,000 kg CO2e for Scope 2. Over the past few years, Servier has demonstrated a commitment to reducing its greenhouse gas emissions, with a target to cut absolute Scope 1 and 2 emissions by 25% by 2030, using 2016 as the base year. Additionally, Servier aims to reduce its Scope 3 emissions, which include emissions from capital goods, waste generated in operations, business travel, and employee commuting, by 25% by 2030. The company also targets a 21% reduction in Scope 3 emissions from downstream transportation and distribution by the same year. Notably, Servier has committed that key suppliers, representing 52% of emissions from purchased goods and services, will establish science-based targets for Scope 1 and 2 emissions by 2024. Overall, Servier's climate commitments align with industry standards, reflecting a proactive approach to sustainability within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 62,044,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 54,578,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - | - |
How Carbon Intensive is Laboratoires Servier's Industry?
How Carbon Intensive is Laboratoires Servier's Location?
Laboratoires Servier's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Laboratoires Servier has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Kubota Pharmaceutical Holdings Co., Ltd.
Frequently Asked Questions
Common questions about Laboratoires Servier's sustainability data and climate commitments